General Information of Drug (ID: DMIMPDL)

Drug Name
PCI-34051 Drug Info
Synonyms
PCI-34259; PCI-34260; PCI-40505; PCI-43744; PCI-45159; PCI-47634; PCI-48000; PCI-48001; PCI-48002; PCI-48003; PCI-48004; PCI-48006; PCI-48007; PCI-48008; PCI-48009; PCI-48010; PCI-48011; PCI-48012; PCI-48013; PCI-48018; PCI-48036; PCI-48039; HDAC 8 inhibitors (cancer/inflammation); HDAC 8 inhibitors (cancer/inflammation), Pharmacyclics
Cross-matching ID
PubChem CID
24753719
ChEBI ID
CHEMBL2170177
CAS Number
CAS 950762-95-5
TTD Drug ID
D0Q5MC

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 2.19 0.00e+0 101/150 (67.33%) SF3A2;HSPA8;SNRPB;...
Ribosome biogenesis in eukaryotes 2.05 0.00e+0 52/108 (48.15%) RPP38;CSNK2A2;LSG1;...
Oxidative phosphorylation 1.87 1.30e-2 93/133 (69.92%) COX7A1;NDUFA4L2;ATP6V1E1;...
Amyotrophic lateral sclerosis 1.80 2.61e-2 267/364 (73.35%) PSMB3;NUP50;COX7A1;...
Inflammatory bowel disease -1.70 4.59e-2 58/65 (89.23%) HLA-DOB;TLR5;HLA-DPB1;...
Glycerolipid metabolism -1.71 4.98e-2 44/61 (72.13%) DGAT1;ALDH2;ALDH3A2;...
Fat digestion and absorption -1.72 4.95e-2 35/43 (81.4%) PLA2G2D;ABCG5;ACAT2;...
Pertussis -1.74 4.26e-2 64/76 (84.21%) C5;CD14;JUN;...
Fatty acid elongation -1.75 4.68e-2 19/27 (70.37%) ELOVL2;PPT2;HSD17B12;...
Malaria -1.79 3.71e-2 44/50 (88%) CD40LG;IFNG;TGFB3;...
Hematopoietic cell lineage -1.84 2.88e-2 90/99 (90.91%) DNTT;CSF2;CD59;...
Cytokine-cytokine receptor interaction -1.86 1.97e-2 246/295 (83.39%) IL2RA;CSH1;IL17B;...
ECM-receptor interaction -1.92 1.75e-2 80/88 (90.91%) CHAD;FN1;COL1A1;...
PPAR signaling pathway -1.96 1.97e-2 66/74 (89.19%) ME3;ANGPTL4;APOA1;...
Steroid biosynthesis -2.10 0.00e+0 19/20 (95%) SOAT1;NSDHL;HSD17B7;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H